Skip to content

Walter H. Kaye

6 papers in the library · 227 citations · publishing 2009-2025

Papers

Sort Most recent Most cited

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa

Journal of Eating Disorders May 26, 2025 Julie Trim, Samantha Shao, Nadav Liam Modlin et al. 14 citations

PT may hold promise not only in the treatment of eating disorders but also trauma-related disorders, including PTSD and dissociative amnesia. Potential mechanisms of psilocybin's facilitation of remembering and processing traumatic material is reviewed.

Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help

Psychedelics. November 7, 2024 Jessie Kim, Samantha Shao, Julie Trim et al. 2 citations

Anorexia nervosa (AN) is a psychiatric illness with high mortality rates and limited treatment outcomes. Psilocybin treatment (PT) has shown promise for various mental health indications and there is significant interest in exploring its potential for AN; however, studies to date are preliminary. Given the probable surge in psychedelic studies for AN, more information is needed to understand...

Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study

FOCUS The Journal of Lifelong Learning in Psychiatry July 1, 2024 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 2 citations

Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7 kg m-2; s.d. 3.7) who met Diagnostic and Statistical Manual of Mental...

Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study

Nature Medicine July 24, 2023 Samantha Shao, Tessa Gruen, Alexandra Babakanian et al. 150 citations

Abstract Anorexia nervosa (AN) is a deadly illness with no proven treatments to reverse core symptoms and no medications approved by the US Food and Drug Administration. Novel treatments are urgently needed to improve clinical outcomes. In this open-label feasibility study, 10 adult female participants (mean body mass index 19.7 kg m − 2 ; s.d. 3.7) who met Diagnostic and Statistical Manual of...

A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression

Clinical Case Reports April 4, 2021 Terry Schwartz, Mary Ellen Trunko, David Feifel et al. 52 citations

Abstract Severe and enduring eating disorders (EDs) have the highest mortality rate of all psychiatric illnesses (Arch Gen Psychiatry, 2011, 68 , 724), especially when comorbid with treatment‐resistant depression (TRD) (Psychiatr Res, 2016, 244 , 45). We report on four patients with enduring EDs and TRD treated with repeat ketamine over 12 + months, showing improvement in depression with only...

5-HT1A receptor activation is necessary for 5-MeODMT-dependent potentiation of feeding inhibition.

Pharmacology, biochemistry, and behavior September 1, 2009 Vikas Duvvuri, Victoria B Risbrough, Walter H. Kaye et al. 7 citations

We propose a translational approach to the study of anorexia nervosa (AN) based on our human subject studies where there are characteristic elevations in 5-HT(1A) receptor binding, associated harm avoidance behaviors, reduced impulsivity, and comorbid anxiety disorders. Towards this goal, the hyponeophagia assay was implemented whereby food-deprived mice show increased latency to begin feeding...